Suppr超能文献

小儿急性淋巴细胞白血病治疗前中心静脉置管的安全性。

The safety of central line placement prior to treatment of pediatric acute lymphoblastic leukemia.

作者信息

Carr Emily, Jayabose Somasundaram, Stringel Gustavo, Slim Michel, Ozkaynak M Fevzi, Tugal Oya, Sandoval Claudio

机构信息

Department of Pediatrics, New York Medical College, Valhalla, New York 10595, USA.

出版信息

Pediatr Blood Cancer. 2006 Dec;47(7):886-8. doi: 10.1002/pbc.20629.

Abstract

BACKGROUND

Central venous lines are placed in children with acute lymphoblastic leukemia at diagnosis, despite significant cytopenias, to facilitate the administration of chemotherapy and blood sampling. The present study aimed to determine the safety of central line placement in these patients.

METHODS

We reviewed the charts of 115 consecutive patients treated during a 10-year period. Data abstracted comprised age, gender, presenting and preoperative blood counts, type of central line, blood products transfused preoperatively, duration of neutropenia (absolute neutrophil count [ANC], <500/microl), treatment, and central line-associated complications.

RESULTS

There were 66 male and 49 female patients with a median age of 4 years. Seventy-one patients were classified as standard-risk and 44 as high-risk. Respective median blood counts at diagnosis and prior to surgery were white cell count (microl), 4,200 and 5,550; hemoglobin (g/dl), 7.7 and 9.4; platelet count (microl), 63,000 and 72,000; and ANC (microl), 3,950 and 4,900. The median duration of neutropenia was 15 days in the standard-risk group and 18 days in the high-risk group. Thirty-eight patients were not transfused preoperatively. There were no episodes of bacteremia. Seven patients (7%) with life-ports experienced a complication: in four blood could not be aspirated, two ports needed realignment, and one a wound infection developed without dehiscence. Four patients (27%) with external lines had a complication: one each with line occlusion, accidental removal by patient, line rupture, and line leakage at insertion site. The complication rate between ports and external lines was different (P = 0.045).

CONCLUSIONS

Central line placement prior to anti-leukemia treatment is safe. Most complications are mechanical and not due to leukemia, chemotherapy, or cytopenias.

摘要

背景

尽管存在明显的血细胞减少症,但在急性淋巴细胞白血病患儿确诊时仍会放置中心静脉导管,以方便化疗药物的输注和血液样本采集。本研究旨在确定在这些患者中放置中心静脉导管的安全性。

方法

我们回顾了10年间连续治疗的115例患者的病历。提取的数据包括年龄、性别、就诊时及术前血常规、中心静脉导管类型、术前输注的血液制品、中性粒细胞减少持续时间(绝对中性粒细胞计数[ANC]<500/微升)、治疗情况以及与中心静脉导管相关的并发症。

结果

共有66例男性和49例女性患者,中位年龄为4岁。71例患者被归类为标准风险,44例为高风险。确诊时及手术前各自的中位血常规结果为:白细胞计数(/微升),4200和5550;血红蛋白(克/分升),7.7和9.4;血小板计数(/微升),63000和72000;ANC(/微升),3950和4900。标准风险组中性粒细胞减少的中位持续时间为15天,高风险组为18天。38例患者术前未输血。未发生菌血症。7例(7%)使用植入式静脉输液港的患者出现并发症:4例无法抽出血液,2例输液港需要重新定位,1例发生伤口感染但未裂开。4例(27%)使用外置导管的患者出现并发症:分别为导管堵塞、患者意外拔除、导管破裂以及插入部位渗漏。输液港和外置导管的并发症发生率不同(P = 0.045)。

结论

在抗白血病治疗前放置中心静脉导管是安全的。大多数并发症是机械性的,并非由白血病、化疗或血细胞减少症引起。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验